Summit Therapeutics plc Summit Presented In Vivo Proof Of Concept Data For Targeted Enterobacteriaceae Antibiotics At Asm/Esc...
05 September 2019 - 9:00PM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
('Summit' or the 'Company')
Summit Presents In Vivo Proof of Concept Data for Targeted
Enterobacteriaceae Antibiotic at ASM/ESCMID Conference
-- New Mechanism Antibiotic has Potential to Overcome Known Resistance
Mechanisms
Oxford, UK, and Cambridge, MA, US, 5 September 2019 -- Summit
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) presented in vivo proof of
concept data for its targeted Enterobacteriaceae antibiotics in animal
models of sepsis, pneumonia and urinary tract infection ('UTI').
Efficacy data of Summit's DDS-04 series of antibiotics was comparable to
marketed antibiotics in all three disease models. These data were
presented in a poster session at the ASM/ESCMID Conference on Drug
Development to Meet the Challenge of Antimicrobial Resistance held in
Boston, MA, September 3-6, 2019. The findings build on previously
reported in vitro studies that showed this new antibiotic class had high
potency and specificity for multiple resistant and non-resistant
Enterobacteriaceae strains.
"Currently marketed broad-spectrum antibiotics for Enterobacteriaceae
infections are failing patients at an increasingly alarming rate due to
rising antibiotic resistance," said Dr David Roblin, President of R&D of
Summit. "Our DDS-04 series works via a new mechanism which has the
potential to successfully cure patients by overcoming all known
bacterial resistance mechanisms. The data presented at ASM/ESCMID show
the promise of our DDS-04 series in combatting Enterobacteriaceae
infections that we estimate cause more than one million infections
annually in the US alone."
Increasing resistance has rendered many marketed antibiotics ineffective
against Enterobacteriaceae. Two Enterobacteriaceae resistance trends
seen in the clinic are on the US Centers for Disease Control and
Prevention's list of urgent and serious bacterial threats. Against the
backdrop of increasing resistance to current antibiotics, there is a
clear need for the development of a new class of antibiotics that could
overcome all known resistance liabilities.
Dr Roblin added, "We designed our DDS-04 series of new class antibiotics
with the aim of treating infections at all sites where resistance is a
clinical issue. That way, we have the chance to make the greatest
positive impact on patients. We are extremely excited by the initial
proof of concept data our DDS-04 series has shown across sepsis,
pneumonia and UTI, and the prospect of moving this series forward."
The DDS-04 series is undergoing lead optimisation.
Details from the poster presentation:
Sepsis Model
-- Non-neutropenic mouse model (CD-1 mice) infected with E. coli
-- Mice dosed intravenously with DDS-04 series representative three times
once every three hours, starting one hour post-infection
-- Tigecycline used as reference, dosed 40mg/kg, two times, once at each of
one and six hours post-infection
-- After nine hours, bacterial burden was below the limit of detection in
the blood, kidneys, liver, lungs and spleen for both the DDS-04 compound
and tigecycline
Pneumonia Model
-- CD-1 mice infected with K. pneumoniae
-- Mice dosed intravenously with DDS-04 series representative three times,
once every eight hours, starting two hours post-infection
-- Tigecycline used as reference, dosed 40mg/kg, three times daily every
eight hours subcutaneously
-- After 26 hours, a 4.5 log10 reduction in bacterial burden was observed in
the lungs for the DDS-04 compound and a similar reduction was observed
with tigecycline
UTI Model
-- C3H/HeN female mice were infected with E. coli
-- Mice dosed intravenously with DDS-04 series representative three times
daily every eight hours over three days
-- Ciprofloxacin used as reference, dosed 10mg/kg, three times daily every
eight hours over three days
-- On day four, a significant reduction in bacterial burden was observed in
the urine, bladder and kidneys for both the DDS-04 compound and
ciprofloxacin
About DDS-04
The DDS-04 series comprises targeted-spectrum compounds that act via a
novel bacterial target, LolCDE. With its new mechanism of action, the
DDS-04 series was rapidly bactericidal and highly potent across globally
diverse Enterobacteriaceae strains in research studies, which included
multi-drug resistant isolates. Importantly, the DDS-04 series has also
shown a low propensity for resistance development and did not show
cross-resistance with existing classes of antibiotics, suggesting the
DDS-04 series has the potential to overcome known resistance mechanisms.
This profile makes the DDS-04 series attractive for further development
for the treatment of Enterobacteriaceae infections.
About Enterobacteriaceae
Enterobacteriaceae are a family of Gram-negative bacteria responsible
for severe and often deadly infections. They account for a significant
fraction of cases across conditions, including bloodstream infections,
hospital-acquired pneumonias and complicated urinary tract infections.
Summit estimates there are more than 1 million infections in the US
annually caused by Enterobacteriaceae across these three settings.
Increasing resistance of Enterobacteriaceae has rendered many marketed
antibiotics ineffective against these bacteria. Two of the most alarming
antibiotic resistance trends are extended-spectrum beta-lactamase
(ESBL)-producing Enterobacteriaceae and carbapenem-resistant
Enterobacteriaceae (CRE). ESBL is an enzyme that allows bacteria to
become resistant to a wide variety of penicillin and cephalosporin
antibiotics. CRE are resistant to nearly all existing antibiotics,
including carbapenems which are considered the antibiotics of last
resort.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for
infections caused by C. difficile, N. gonorrhoeae and ESKAPE pathogens
and are using our proprietary Discuva Platform to expand our pipeline.
For more information, visit www.summitplc.com and follow us on Twitter
@summitplc.
Contacts
Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated
Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate
Finance
Tom Salvesen, Corporate Broking
Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500
Phil Walker / Dominic Wilson
MSL Group (US) Tel: +1 781 684 6557
mailto:summit@mslgroup.com
Jon Siegal summit@mslgroup.com
---------------------------------
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Sukaina mailto:summit@consilium-comms.com
Virji / summit@consilium-comms.com
---------------------------------
Lindsey Neville
Summit Forward-looking Statements
Any statements in this press release about the Company's future
expectations, plans and prospects, including but not limited to,
statements about the clinical and preclinical development of the
Company's product candidates, the therapeutic potential of the Company's
product candidates, the potential commercialisation of the Company's
product candidates, the sufficiency of the Company's cash resources, the
timing of initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing approvals
and other statements containing the words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "would," and
similar expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including: the uncertainties inherent in the initiation of future
clinical trials, availability and timing of data from ongoing and future
clinical trials and the results of such trials, whether preliminary
results from a clinical trial will be predictive of the final results of
that trial or whether results of early clinical trials or preclinical
studies will be indicative of the results of later clinical trials,
expectations for regulatory approvals, laws and regulations affecting
government contracts and funding awards, availability of funding
sufficient for the Company's foreseeable and unforeseeable operating
expenses and capital expenditure requirements and other factors
discussed in the "Risk Factors" section of filings that the Company
makes with the Securities and Exchange Commission, including the
Company's Annual Report on Form 20-F for the fiscal year ended 31
January 2019. Accordingly, readers should not place undue reliance on
forward-looking statements or information. In addition, any
forward-looking statements included in this press release represent the
Company's views only as of the date of this release and should not be
relied upon as representing the Company's views as of any subsequent
date. The Company specifically disclaims any obligation to update any
forward-looking statements included in this press release.
-END-
(END) Dow Jones Newswires
September 05, 2019 07:00 ET (11:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024